Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
BOTHELL, Wash., March 27, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) today announced that it will host a conference call and simultaneous webcast Monday, March 28, 2016, at 8:30 a.m. ET, to review top-line data from its Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine and top-line data from its Phase 1 clinical trial evaluating multiple doses of ALD403 through various modes of administration in healthy volunteers.
Conference Call Details
The live call may be accessed by dialing 877-430-4657 for domestic callers or 484-756-4339 for international callers, and providing conference ID number 80096426.
The webcast, with slides, will be broadcast live on the Events & Presentations page of the Investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 [email protected]
